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1. Introduction
Inflammation is a very complex reaction to infection or injury the endeavour being to contain
the infection and harm to a limited area. The process is associated with the activation of the
coagulation system. To think that inflammation occurs and then leads to activation of the
coagulation system is not quite true as there is much cross-talk between the two systems. This
is a natural host response to cellular damage or infection however an overshooting of this cross-
talk between coagulation and inflammation can lead to an exaggerated prothrombotic state
and exacerbate the disease process. A wide range of inflammatory conditions such as infec‐
tions, acute respiratory distress syndrome and SIRS (systemic inflammatory response syn‐
drome) following major surgery e.g.cardiac surgery can lead to an uncontrolled inflammatory
response and to profound disturbance of the coagulation system leading to an imbalance in
the normal anticoagulated state of blood to that of a procoagulant state. When coagulation is
compromised it can contribute to the pathogenesis of the inflammatory condition with
deposition of fibrin within the microvasculature directly enhancing the inflammatory reaction.
This in turn leads to a modulation of protein manufacture mainly via Liver hepatocytes in the
upregulation and downregulation of at least twenty factors directly involved in blood
coagulation. This process is controlled via cytokines and leads to the imbalance in what are
called the haemostatic acute phase proteins. All of which puts the haemostatic system at an
increased thrombotic potential [1, 2, 3, 4].
The haemostatic system maintains blood in a fluid phase under normal physiological condi‐
tions and provides a mechanism to prevent exsanguination upon vascular damage. Morawitz
had created the ‘classic’ theory of blood coagulation in 1905 but it was Macfarlane who first
reported the coagulation cascade as a biochemical amplification pathway of pro-enzyme-
enzyme transformations in 1964 [5]. Davie and Ratnoff later the same year referred to it as a
waterfall stepwise sequence of activation [6]. Macfarlane’s idea that amplification of the
cascade and acceleration of earlier stages of the pathway culminating in the conversion of
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fibrinogen to fibrin was a major breakthrough in the understanding of how the coagulation
factors interacted and forms the basis of what we understand today.
Platelets are the primary haemostatic plug when damage first occurs to a vessel. The multi‐
meric protein von Willebrand factor mediates the adhesion of platelets to the site of vascular
damage. The platelets bind to the matrix proteins exposed by the damage to the vessel wall,
particularly collagen. These platelets are activated by small amounts of thrombin (~1nM)
produced by tissue factor exposure at the site of vascular damage. The tissue factor binds factor
VII that is rapidly activated. The tissue factor-VIIa complex subsequently activates factor X.
The activated platelet provides binding sites for the coagulation enzymes, localising coagula‐
tion to the site of injury and prolonging activation of coagulation by protecting the enzymes
from inhibition and inactivation [7]. Factor X is essential to this ‘propagation’ phase of
coagulation. When bound to the platelet and activated via the VIIIa-IXa complex Xa is
protected from inhibition by tissue factor pathway inhibitor and antithrombin.
Figure 1. Cell based model coagulation. Reproduced with kind permission of Professor M.Hoffman
Tissue factor pathway inhibitor (TFPI) rapidly blunts this driving force of tissue factor-VIIa
complex that initiates coagulation and generates the sudden burst of thrombin [8]. Once trace
amounts of thrombin have been formed this is then able to activate factors V, VIII, IX and XI.
This positive feedback mechanism ensures prolonged activation of the system with sufficient
quantities of thrombin being produced to activate platelets, white cells, endothelial cells, and
the protein C anticoagulant pathway and to continue producing thrombin.
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Coagulation activation yields proteases that not only interact with coagulation protein
zymogens but also with specific cell receptors to induce signaling pathways that mediate
inflammatory responses [9]. Many in vitro observations point to a role of coagulation proteases
in upregulating the expression of proinflammatory mediators [10]. The most important
mechanism by which coagulation proteases influence inflammation is by binding to protease
activated receptors (PARs), of which four types (PAR 1 to 4) have been identified, all belonging
to the family of transmembrane domain, G-protein–coupled receptors [11]. Tissue factor is also
a potential mediator of intracellular signaling of established inflammatory pathways, func‐
tioning as an intermediate for factor VIIa–induced activation of mitogen-activated protein
kinases and calcium signalling [12]. It is tissue factor that binds to factor VII and drives
thrombin generation leading to fibrin formation. Tissue factor is an integral membrane protein
normally separated from blood by the vascular endothelium. Tissue factor is expressed in the
vascular adventitia in astroglial cells. It also appears in tumour cells where it appears related
to their metastatic potential. All of this activation of coagulation increases in some procoagu‐
lant factors (fibrinogen and fator VIII) with reduced fibrinolytic response and dampening of
the natural anticoagulant potential have a profound effect on mortality.
Thrombin plays many parts (Figure 2) and with the anticoagulant protein, activated protein
C, can activate specific cell receptors on mononuclear cells and endothelial cells which can
affect cytokine production and inflammatory cell apoptosis.
Vascular endothelium
Thrombin
VIII V
XIII
XI
Leukocyte
Platelet
Fibrinogen
Activated protein C
TM
TAFI
t-PA
ICAM-1 P-selectin
Figure 2. Thrombins role in activating some of the components of coagulation and inflammation. Coagulation factors
V, VIII,XI and XIII, TM – thrombomodulin, TAFI – thrombin activatable fibrinolytic inhibitor, t-PA – tissue plasminogen
activator, ICAM-1 intracellular adhesion molecule 1
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2. Initiation of the pro-inflammatory response
Pathogen recognition receptors, Toll receptors (TLR), are essential in the host defence against
pathogens. Platelets express these pattern recognition receptors involved in innate immunity.
TLR’s recognise microbial structures that are conserved among species. TLR1,2,4 6,8 & 9 all
appear on platelets and form one of the many bridges between inflammation and coagulation.
TLR’s are responsible for LPS induced thrombocytopenia [13]. Platelets express TLR – pattern
recognition receptors involved in innate immunity. TLR’s are able to recognise danger
associated molecular patterns (DAMPs). For example fibrinogen that is released during
inflammation is a DAMP and further enhances the proinflammatory response through TLR4.
It is via TLR and DAMPs that induction of caspase-1 activation which causes the processing
of the proinflammatory response through various cytokines [14]. Figure 3
Figure 3. Cross-talk between coagulation and innate immune pathways in response to DAMPs (danger associated
molecular patterns); DAMPS from invading pathogens or damaged host cellsare recognised by pathogen recognition
receptors (PRRs) on antigen presenting cells, neutrophils, monocytes, macropahges, endothelial cells and platelets.
This results in tissue factor exposure sustained by cytokines and chemokines with proinflammatory and opsonic prop‐
erties and associated with increaased expressionof leukocyte adhesion molecules. In parallel DAMP-induced comple‐
ment activation via any of the complement activation pathways leads to generation of the complement factors C3a
and C5a and the membrane attack complex C5b-9. C5a feeds back to promote further tissue factor expresssion and
C5b-9 also supports generation of thrombin. Green lines indicate increase in response, red lines indicate supression.
Reproduced with kind permission of Dr EM Conway.
Cytokines are small molecules that have relatively short half-lives of between minutes and
hours but play a pivotal role in the inflammatory response. The most important cytokines
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involved in regulating the coagulation response during inflammation are IL-6, TNF-alpha,
IL-8, MCP-1 and IL-1 [15].
Acute phase proteins are released as mediators of the inflammatory cascade as a chemical and
cellular response to injury. They increase rapidly in plasma in response to a inflammatory
insult. Some acute phase proteins increase transiently (C-reactive protein) while others have
a more sustained elevation (Haptoglobin) [16].
The inflammatory response to surgery, atherosclerosis, infection and cardiovascular disease
has a profound effect upon the haemostatic system, including fibrinolysis. The cytokines
interleukin 1β (IL-1β) and interleukin 6 (IL-6) modulate the production and suppression of
many of the coagulation enzymes formed by the Liver.
The effect is to make the endothelium and whole coagulation system more procoagulant.
Figure 4
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Figure 4. Inflammatory drive to a procoagulant state following endothelial stimulation.
3. Coagulation acute phase proteins
An acute-phase  protein  has  been  defined  as  one  whose  plasma concentration  increases
(positive acute-phase proteins) or decreases (negative acute-phase proteins) by at least 25
percent during inflammatory disorders [16].  The changes in the concentrations of  acute-
phase proteins are due largely to changes in their  production by hepatocytes.  Although
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the  mechanism  by  which  the  liver  processes  the  stimulation  to  increase  and  decrease
protein production may be different in different forms of inflammatory insult e.g. sepsis
and chronic inflammation [17].
Proteins whose plasma concentrations increase with
inflammation
Proteins whose plasma concentrations decrease with
inflammation
Fibrinogen
Factor VIII
Protein S
Plasminogen activator inhibitor PAI-1 C4b-binding
protein
Urokinase
α 1 Antitrypsin
α 2 Macrogloulin
von Willebrand factor
C1-esterase inhibitor
C-reactive protein
Thrombopoietin
Thrombin activatable fibrinolytic inhibitor (TAFI)?
Factor XII
Antithrombin
Histidine rich glycoprotein
Thrombomodulin
Endothelial protein C receptor
Thrombin activatable fibrinolytic inhibitor TAFI?
Protein C (? No change/decrease)
Table 1. Acute phase proteins that directly affect haemostasis
4. Coagulation proteins whose plasma concentrations increase during
inflammation
4.1. Fibrinogen
Fibrinogen is a soluble glycoprotein synthesised in the Liver with a normal plasma concen‐
tration of 2 – 4 g/L and half life of 4 days. When the coagulation cascade is activated fibrinogen
is the final substrate in the formation of a clot being converted to its insoluble fibrin form.
Thrombin cleaves fibrinogen releasing fibrinopeptide A and B forming fibrin monomers which
have exposed polymerisation sites on the fibrin molecule. Thrombin activates factor XIII which
cross-links these fibrin fibrils increasing clot strength and rendering them more resistant to
proteolysis [18]. Fibrin creation is required with platelets (stimulating platelet aggregation by
binding to the glycoprotein IIb/IIIa platelet membrane receptor) to repair any breach in the
vascular integrity and prevent haemorrhage. This process is not left unchecked and is
regulated via the fibrinolytic system (plasmin production) to prevent excess fibrin accumula‐
tion at the site of damage despite the procoagulant signalling drive. The local production of
plasmin is regulated via two plasminogen activators, tissue plasminogen activator (t-PA) and
urokinase plasminogen activator (u-PA) which under normal physiological conditions keeps
this fibrin matrix production and its lysis tightly controlled [19].
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During an inflammatory reaction fibrinogen can increase in the order of 2-3 fold and this
will  significantly increase blood viscosity and cause some degree of red cell  aggregation
as well  as transform vascular pathologies such as atherosclerotic plaques.  Fibrinogen by
means of  increasing the production of  endothelin-1,  is  also capable  of  directly  inducing
vasoconstriction [18].
Figure 5. Fibrinogen and fibrin modulation of inflammation. Fibrin(ogen) modulates the inflammatory response by
affecting leukocyte migration but also by induction of cytokine/chemokine expression mostly via Mac-1 signalling.
NO-nitric oxide, Mac-1 Macrophage antigen 1, PI3K Phosphoinositide-3-kiniase, TNF tumor necrosis factor. Repro‐
duced with kind permission of Prof. K Zacharowski
There is good evidence that fibrinogen has a function in regulation of the inflammatory
response as is seen in the increased concentration of fibrinogen associated with atherosclerosis
and cardiovascular risk. Fibrin(ogen) also participates in activation of vascular cells and
regulation of the inflammatory response via the ability to bind to and activate a number of
immune cells. The cellular ligand binding of fibrinogen is totally distinct to any coagulation
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function. Fibrin(ogen) can bind to the integrin receptor Mac-1 which is found on many myeloid
cells including monocytes and neutrophils and also T cells. The Mac-1 integrin is involved in
phagocytosis, adhesion, migration through the endothelium as well as apoptosis and degra‐
nulation (Figure 5). Binding of fibrinogen to Mac-1 also induces production of cytokines IL-1β,
IL-6 and TNF-α potentiating the inflammatory response, as many acute phase proteins do [20].
When fibrin is laid down in the microvasculature bed this enhances local and systemic
inflammation via expression of proinflammatory mediators. Fibrin(ogen) increases mRNA
concentration and induces synthesis of the proinflammatory cytokines IL-6 and TNF-α in
monocytes and macrophages which is induced by chemokine expression, macrophage
chemotactic protein (MCP-1) and macrophage inflammatory protein (MIP-1 and 2). The Toll
receptor TLR 4 facilitates this fibrin(gen) chemokine expression signalling [20].
Breakdown products of fibrin, D-dimers stimulate monocytes to release the following IL-1,
IL-6 and PAI-1 and fibrin degradation products also induce C-reactive protein production.
4.2. Factor VIII
Factor VIII is a procoagulant whose deficiency leads to classical haemophilia and a bleeding
diathesis [21]. Factor VIII once activated by small amounts of thrombin becomes a co-factor
for activated factor IXa in the formation of the tenase complex whereby these catalysts convert
factor X to its activated form Xa. A number of publications have shown raised factor VIII to be
linked with venous thromboembolism and increased thrombin generation [22, 23]. This
increase in factor VIII has been linked with an increase in basal inflammatory reaction. Factor
VIII increased production is mediated by the cytokine IL-6, however it is debateable as to how
much a persistently raised factor VIII is responsible to inflammation by some [24]. Post
operatively particularly after cardiac surgery factor VIII can be raised by as much as 2-3 fold.
4.3. Protein S
Protein S is a co-factor for protein C and produced mainly in the hepatocyes but also endothelial
cells and megakaryocytes. Once protein C has been activated by the thrombin thrombomo‐
dulin complex, which is augmented by the endothelial protein C receptor, activated protein C
dissociates from the endothelial protein C receptor and binds with protein S. This complex is
then able to inhibit factors Va and VIIIa, protein S enhancing the reactive cleaving of specific
sites by APC on factors V and VIII by anything up to 20-fold. At any one time only approxi‐
mately 40% of circulating protein S is free and able to participate in this reaction. The remaining
60% of circulating protein S is bound to the complement regulator protein C4B-binding protein
and lacks the co-factor functionality in this reaction. Consequently the protein S-C4BP complex
limits the functionality of activated protein C in its anticoagulant role. Therefore protein S plays
an important role in the regulation of thrombin generation although it being a risk factor for
venous thrombosis in deficient patients remains unclear and the odds risks have varied
between 0 – 11.5 fold in protein S deficient cases.
Protein S has an accelerating role in APC mediated PAI-1 inhibition thereby promoting clot
lysis and a possible inhibition of activation of thrombin activatable fibrinolytic inhibitor [25].
Acute Phase Proteins38
Protein S has been shown to increase during inflammation. This may in part be due to
counterbalancing the procoagulant drive of the coagulation system in these circumstances by
providing more anticoagulant effect via the protein C pathway. It may also have to do with
other non-anticoagulant actions it has via its binding with C4BP (see below). Certainly
inhibition of protein S in in-vivo models of bacteraemia have shown to provoke the cytokine
response and what was a non-lethal injected dose of E.coli in baboons resulted in a lethal
reaction [26].
4.4. C4b-binding protein
The complement binding protein C4BP is a co-factor to a serine protease in the degredation of
C4 in the classical complement pathway and providing it has been suggested protection from
inflammation at a cellular level. The C4BP molecule has a central region with seven α chains
and one β chain emanating from it each with distinct ligand binding regions. It is on the β
chain side arm that the protein S binding region resides and in normal human plasma ~80%
of C4BP is found as this β chain form. C4BP is an acute phase protein and its levels can increase
to 400% of normal [25]. However this is mainly of the C4BPα form so the Protein S-C4BP
complex concentration is not generally affected. As so much protein S is normally bound to
C4BP and the concentration of the free anticoagulant active co-factor protein S level quite
tightly controlled is there a physiological role for the PS-C4BP complex? It has been suggested
that protein S forms one of the bridges between coagulation and inflammation. As protein S
has a high affinity to bind to negatively charged phospholipids it can bring C4BP into close
proximity to these sites allowing controlled complement activation at areas of vascular damage
where coagulation is activated. This has been linked to apoptosis and the complement system
allowing rapid clearance of apoptotic cells from the site of damage by macrophages but more
probably limiting or inhibiting further complement activation via necrotic cells [27, 28].
4.5. Plasminogen activator inhibitor PAI-1
The fibrinolytic system is the opposite of the coagulation system. It limits clot formation to the
site of injury and breaks down existing clot by an enzyme cascade. It is also, like haemostasis,
linked to inflammation with acute phase proteins that increase and others that are decreased.
Plasminogen provides the fibrinolytic potential and when converted to its active form plasmin
is able to bind to fibrin and begin its degradation. Plasminogen is activated by two activators,
tissue plasminogen activator (t-PA) and urokinase tissue plasmingen activator (u-PA). These
in turn are inhibited by plasminogen activator inhibitor 1 and 2 (PAI-1, PAI-2) and plasmin is
inhibited by α-2-antiplasmin. Of these inhibitors PAI-1 is a positive acute phase protein and
increases during inflammation. The cytokine tissue necrosis factor
(TNF-α) suppresses finbrinolysis by down regulating t-PA expression in endothelial cells
while production PAI-1 then in turn PAI-1 inhibits TNF-α is inhibited by PAI-1. It has also
been shown that by inhibiting TNF-α plasma levels of PAI-1 decrease [19].
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The increase in PAI-1 levels is again a driver of the haemostatic system towards a more
prothrombotic state. PAI-2 will not be discussed here but for interested readers they are
directed to the following publication [29].
4.6. Urokinase
Urokinase plasminogen activator (u-PA) is a multifunctional serine protease. It has been
shown to act as both a signalling ligand and a proteolytic enzyme. As an acute phase protein
its increase has been found in a number of metastatic carcinomas and this has led to a link in
its role of tumor growth and cellular expansion in conditions such as cardiac fibrosis and
atherosclerosis [30]. As well as displaying involvement in tissue remodelling u-PA also
appears to regulate macrophage activation and function. The macrophages not only synthesis
and release u-PA but also have receptors for the u-PA protease on their membranes. The
excreted u-PA induces TNF-α synthesis and secretion. The u-PA molecule has also been shown
to initiate inflammation via the release of IL-6 and IL-1β from monocytes and lymphocytes
[31]. The u-PA and its receptor uPAR also mediate immune complex induced inflammation
in the lung. This is achieved via generation of u-PA at the site of cellular inflammation with
subsequent activation of its receptor uPAR. This then sets off cellular signalling with C5a/C5aR
on the alveolar macrophages, recruitment of polymorphonuclear leukocytes and adequate
TNF-α production [32].
4.7. α 1 Antitrypsin
The α-1-antitrypsin glycoprotein is a proteinase inhibitor synthesised and secreted in the
hepatocytes of the Liver. It is one of two physiological inhibtors of activated protein C. It also
has a profound anti-inflammatory effect in the lungs with concentrations during a inflamma‐
tory response reaching levels found in the plasma. The range of antiprotease activity seen in
the lungs includes neutrophil elastase and plasminogen acitvators. If there is a deficiency of
α-1-antitrypsin (as with the genetically abnormal SERPINA1 gene mutations) then neutrophil
elastase provoked by infection and inflammation will unchecked breakdown elastin and
destroy alveolar walls leading to emphysema [33].
4.8. Alpha-2-macroglobulin
Alpha-2-Macroglobulin (α-2M) is an ancient serine protease binding host or foreign peptides
and particles, thereby serving as humoral defense barrier against pathogens in the plasma and
tissues. In humans α-2M, interacts and captures virtually any proteinase whether self or
foreign, suggesting a function as a unique "panproteinase inhibitor." In adult humans it
provides somewhere between 10-25% of the overall anti-thrombin activity in plasma. It is also
the primary inhibitor of thrombin in neonates and infants under 1 year of age until the Liver
matures and begins producing sufficient Antithrombin to take over the role. At times of
inflammation when antithrombin levels are low α-2M can become a ‘back-up’ thrombin
inhibitor [34].
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4.9. C1-esterase inhibitor
C1-inhibitor (C1INH) is a serpin and major inhibitor of the contact coagulation system that
involves factor XII, kallikrein and kininogen. It is also an important regulator of complement
activation inhibiting the first component of complement C1. Another important biological role
of C1INH is vascular permeability regulation [35]. This is well illustrated in patients who suffer
from hereditary angioedema where there is a deficiency of the C1INH activity. As it now seems
factor XII plays a substantial part in the formation of thrombin during sepsis and inflammation
where neutrophil extracellular traps are present that release polyphosphate that in turn
activate factor XII it would appear normal for C1INH to act as a positive acute phase protein
in limiting this activation as well as its complement inhibitory role. A rapid appearance of
C1INH-factor XIIa complexes is reported during sepsis with a sharp fall in the C1INH activity
wherein the inhibitory function of α-2Macroglobin becomes more important in its kallikrein
inhibiting role [36].
4.10. von Willebrand factor
The von Willebrand factor (VWF) is a multimeric protein that mediates the adhesion of
platelets to the exposed subendothelium at the site of vascular injury. It also serves as a carrier
protein for the labile coagulation factor VIII. VWF is synthesised in and stored in the Weibal-
Palade bodies of endothelial cells and megakaryocytes/platelets. Endothelial cells release VWF
when activated or stimulated. These VWF molecules are ultralarge and hyperactive, proficient
in binding to platelets via the glycoprotein Ib-X-V complex without any external activation.
Normally the ultralarge VWF multimers are cleaved into smaller less active multimers before
being released into plasma. Cleavage is performed by ADAMTS-13 (a disintegrin and metal‐
loprotease with thrombospondin motif). A deficiency of ADAMTS-13 leads to a thrombotic
thrombocytopenic purpura a thrombotic microangiopathy. Increased plasma levels of VWF
have been reported in a number of disease states including coronary artery disease, autoim‐
mune disease, trauma and infections. A common underlying process in all of these is inflam‐
mation. There appears to be a complex interaction between the common inflammatory
cytokines IL-6, IL-1β and TNF-α the release and cleavage of the VWF multimers by
ADAMTS-13.
Release of VWF multimers from endothelial cells occurs in a dose dependent fashion when
stimulated with IL-8 and TNF-α and IL-6 inhibits cleavage of the ultrlarge multimers. This
demonstrates that inflammatory cytokines interfere with the equilibrium of release and rate
of cleavage of the ultralarge VWF multimers.
This increases prothrombotic risk in this setting as most of the positive acute phase proteins
have a propensity to do creating a procoagulant environment. It is of interest to note that IL-8
resides in the Weibel-Palade bodies of the platelet the same place as VWF and is involved in
the platelet leukocyte aggregation and it is TNF-α that activates endothelial cells releasing IL-8.
The inhibition by IL-6 of ultralarge multimer cleavage by ADAMTS-13 may be by way of
synthetic and secretion inhibition. In overwhelming sepsis there is also probably an element
of exhaustion of metalloprotease activity [37].
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4.11. C-reactive protein
C-reactive protein (CRP) is a pentameric molecule that increases several hundred fold
following an inflammatory stimulatory response this being primarily due to IL-6 stimulation
of production of CRP in the hepatocytes of the Liver. CRP amplifies the host defence mecha‐
nism by activation of complement via C1 and stimulation of macrophages. CRP also upregu‐
lates tissue factor expression on monocytes [38] and induces release of PAI-1 thereby
downregulating fibrinolysis [39] promoting a procoagulant state. The pentameric CRP is
thought to be directly proinflammatory at high concentration like those of sepsis or major
surgery but more subtle inflammatory reactions take place when monomeric CRP is released
from the pentameric form. This appears to be driven by activated platelets revealing new lipid
messenger sites; lysophosphatidycholine (LPC) that bind and dissociate the pentameric form
of CRP to the monmeric form [40].
During sepsis when disseminated intravascular coagulation (DIC) occurs this has been found
experimentally to co-inside with formation of a calcium-dependent complex between CRP and
very low density lipoprotein (VLDL). The VLDL molecular makeup is different in septic
patients to normal controls due to a deficiency of phosphatidylethanolamine. This CRP-VLDL
lipid raft increases the procoagulant effect through an increase in prothrombinase activity. The
CRP-VLDL complex exists in vivo and it has been postulated that is has a pathogenic role in
disseminating the intravascular coagulation [41].
5. Coagulation proteins whose plasma concentrations decrease during
inflammation
5.1. Antithrombin
Antithrombin (AT) is one of the major natural anticoagulats inhibiting thrombin, factor Xa,
IXa and factor VIIa bound to tissue factor. Inhibition of factors Xa, IXa and the VIIa-tissue factor
are accelerated via the endothelial cell heparin like proteoglycans. The importance of this
anticoagulant pathway is highlighted when AT levels are low, either congenitally or acquired,
the risk of thrombosis is significantly increased.
AT has been shown in-vitro using HUVEC cells and IL-6 to act as a negative acute phase protein
[42]. Other mechanisms that can reduce AT function during an inflammatory response include
increased consumption from activation of haemostasis and increased degradation by proteo‐
lytic enzymes (elastase released from activated neutrophils). Furthermore inflammatory
cytokines can induce a reduction in the production of glycosaminoglycans such as heparin
and chondroitin sulphate on the endothelial cell which may contribute to the impaired function
of AT due to GAGs acting as physiological heparin-like cofactors promoting the anticoagulant
anti-thrombin activity of AT [43, 44].
AT can indirectly act as an anti-inflammatory molecule by directly inhibiting thrombin
reducing its inflammatory properties of haemostatic and complement activation, leukocyte,
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endothelial and platelet activation. AT also appears to directly act as an anti-inflammatory
agent by binding with leukocytes receptors blocking their communication with endothelial
cells and limiting their adhesion and migration [45]. In animaI models it has also been shown
that AT induces the release of prostacyclin from endothelial cells. The prostacyclin is a platelet
inhibitor and abrogates neutrophils adhering to endothelial cells both of which contribute to
the inflammatory response [46].
In addition AT can also modulate cellular receptor expression by downregulating the expres‐
sion of CD11b/CD18 on leucocytes which bind factor X aiding its activation [47].
AT is also able to decrease expression of tissue factor and IL-6 expression on monocytes and
endothelial cells reducing the inflammatory drive [48].
5.2. Histidine rich glycoprotein
Histindine rich glycoprotein (HRGP) is a single polypeptide chain protein that is synthesised in
the Liver found in plasma and on the surface of leukocytes, monocytes and the α-granules of
platelets. HRGP has been shown to bind to a number of molecules including, haem, Zn2+,
plasminogen, fibrinogen, IgG, complement and factor XIIa (not the inactive zymogen) [49].
HRGP exerts some degree of innate immune response by exhibiting antimicrobial activity to
some organisms and removal of necrotic cells by binding to free decondensed DNA (polyphos‐
phate).
HRGP behaves as a negative acute protein during inflammation [50]. This is of interest as
fibrinogen one of its primary ligands is increased. Possibly more importantly is the fact that
HRGP strongly inhibits polyphosphate induced factor XII autoactivation via increased Zn2+
levels in response to local platelet activation, showing it to be a significant modulator of factor
XII activation during sepsis and inflammation [51]. Because of its negative acute phase nature
this will allow increased activation of factor XII in these circumstances potentiating the pro-
inflammatory and pro-coagulant condition.
5.3. Thrombomodulin
Thrombomodulin (TM) is present on endothelial cells of the entire vasculature and is a
transmembrane protein with epidermal growth factor (EGF) repeating molecules that stick out
of the plasma membrane and provide binding and activation sites for a number of molecules.
There is a high affinity binding site for thrombin on EGF domain 5-6 from which protein C is
activated at EGF domains 4-6. Thrombin activatable fibrinolytic inhibitor is activated by
thrombin at EGF sites 3-6 [52]. When thrombin binds and complexes with thrombomodulin
on the cell membrane its ability to activate protein C increases by greater than 1000-fold.
Activated protein C anti-inflammatory effects are discussed later in this chapter, see below.
Once thrombin has bound to TM it becomes quickly neutralised by its natural serine proteases
inhibitors antithrombin, heparin co-factor II and protein C inhibitor and therefore activation
of protein C also ceases.
The effect of inflammation on TM is to decrease its presence on the endothelial cell surface by
its cellular internalisation by endocytosis via TNF-α. This creates a site where coagulation can
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take place as the anticoagulant barrier has been removed and it may also stimulated further
inflammatory response [43]. CRP has also been shown in experimental conditions using
human coronary artery endothelial cells treated with CRP in a dose and time dependent
manner to reduce messenger RNA levels of TM [53]. TM also provides anti-inflammatory
protection from complement activation by enhancing inactivation of C3b and by promoting
activation of thrombin-activatable fibrinolysis inhibitor that inactivates complement anaphy‐
latoxins C5a and C3a [54]. Others have shown that thrombin-activatable fibrinolysis inhibitor
activation via TM is attenuated by platelet factor 4 released from activated platelets [55].
5.4. Endothelial protein C receptor
The thrombomodulin-thrombin conversion of protein C to its activated form is facilitated by
the endothelial protein C receptor (EPCR). The EPCR is another endothelial cell transmem‐
brane protein located in close proximity to the thrombomodulin molecule and with high
affinity binding for protein C. EPCR as well as binding protein C also binds its activated form
and via membrane lipid rafts they complex with PAR-1 [56]. The EPCR-activated protein C
molecule activates PAR-1 in a different way to thrombin which allows it to signal through a
potent Gi protein pathway by which anti-inflammatory pathways are stimulated within the
endothelial cell [57]. C-reactive protein has also been shown, as in the case of thrombomodulin,
under experimental cell culture conditions to down regulate EPCR.
5.5. Thrombin activatable fibrinolytic inhibitor
Thrombin activatable fibrinolytic inhibitor (TAFI) is a basic carboxypeptidase identical to the
plasma procarboxypeptidases B, U and R. TAFI is activated by thrombin and plasmin although
the most efficient activator is the thrombomodulin-thrombin cellular membrane bound
complex. TAFI inhibits fibrinolysis by cleaving lysine residues from fibrin which restricts the
binding of tissue plasminogen activator to these sites and enhancing the plasminogen con‐
version to plasmin potentiating further fibrin breakdown [58]. TAFI certainly modulates the
balance between coagulation and fibrinolysis but it appears its linking role with inflammation
still needs to be fully elucidated. For instance TAFI has been shown to be a positive acute phase
protein in mice [59] but in the same year Boffa et al interestingly showed that IL-6 administered
to cultured HepG2 cells resulted in a 60% decrease in TAFI mRNA [58]. Subsequently TAFI
has been shown to be raised in experimental endotoxemia [60]. Its anti-inflammatory proper‐
ties are also downregulated by platelet factor 4 which is release from activated platelets and
endothelial cells during activating stimuli and inflammatory insults which prevents TAFI
activation by binding to the thrombin-thrombomodulin complex thereby preventing TAFI’s
inactivation of the complement anaphylatoxins C5a and C3a [55].
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6. Other major components of the acute phase response that affect
haemostasis
6.1. Protein C
The protein C pathway is known to be an important anticoagulant system with patients
deficient in protein C being at risk of thrombosis or in its homozygous form purpura fulminans.
Activated protein C inhibits factors V and VIII this being supported by the activation of protein
C by thrombin bound to thrombomodulin on the endothelial cell surface. As well as acting as
an anticoagulant activated protein C is also able to inhibit PAI-1. The anticoagulant and
antifibrinolytic aspects of the protein C pathway have been elucidated and well described
although there still appears much to learn from the interaction of protein C during the
inflammatory response.
It is unclear from studies of the acute phase proteins whether protein C acts as a positive or
negative acute phase protein. Most studies show it to have no change in concentration during
an inflammatory response or its plasma concentration to decrease. A decrease in protein C
could be attributed to consumption as well as a cytokines limiting the natural anticoagulant
response. Activated protein C also confers a cytoprotective, anti-inflammatory, anti-apoptosis
and endothelial barrier stabilisation effect when active [61].
Activated protein C signals its anti-inflammatory effects mainly via PAR-1 pathways whereby
following Gi signalling and sphingosine-1-phosphate production there is improvement in
endothelial cell barrier function [62].
Transcriptional profiling studies using cell cultures of human umbilical vein endothelial cells
(HUVECs) have demonstrated that recombinant human activated protein C can regulate
endothelial cell gene expression linked to inflammation and cell survival [63]. The activated
protein C suppresses NFκB a cell nuclear transcription factor, and by reducing its expression
and function this in turn causes inhibition of cytokine signaling [64].
6.2. Cytokines
Cyotkines are a superfamily of molecules involved in cell signalling many of which are
increased greater than 1000-fold during an inflammatory insult. Cytokines such as interleukin
(IL)-6, but also platelet-derived growth factor and monocyte chemoattractant protein (MCP)-1
are capable of stimulating tissue factor expression in mononuclear cells. Tissue factor being
the initiator of thrombin generation and fibrin formation.
IL-6 is a multifunctional cytokine that is induced in many disease states such as sepsis,
endotoxaemia and in-vitro after administration of tumor necrosis factor (TNF). Several studies
have suggested IL-6 to be a potential mediator of endotoxin induced coagulation activation.
This has been validated by treatment of chimpanzees with a monoclonal anti-IL6 antibody that
ablated the activation of coagulation [65]. Cytokines are pivotal in providing a means of cross
talk between inflammation and coagulation [66].
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Inflammation and coagulation can not be considered as two separate processes because there
are several interlocking points making them a unique defensive host reaction. The endotheli‐
um is one of the major links between the two since damaged endothelium during inflammation
represents a surface where proteins involved in both coagulation and fibrinolysis and the
development of inflammation are expressed. Cytokines down regulate the surface receptor
thrombomodulin and the activation of protein C but at the same time increase the expression
of tissue factor. Platelets adhere to these sites of vascular damage and when activated also
release several cytokine mediators of inflammation, adhesion molecules and growth factors
including IL-1β, CD40 ligand, vitronectin and RANTES [13], [67].
In addition to the inflammatory cytokines like interleukin 1 and TNF, infection per se can
trigger the release of neutrophil extracellular traps (NETs). Which in turn release cytokines
and microparticles exacerbating the acute phase haemostatic response [68].
Cytokines also upregulate the complement system activated C5b9 complexes can assemble
clot promoting membrane phospholipids, TNF-α downregulates thrombomodulin and
vascular heparin sulphates promoting a procoagulant environment. The net effect of this is to
further lessen the inhibitory mechanisms that control thrombin generation.
6.3. Platelets
Platelet numbers increase following surgery, trauma and sepsis following a inflammatory
response. Both IL-6 and thrombopoetin stimulate the production of platelets [69]. This reactive
thrombocytosis can last up to13 days post surgery and may responsible for PAF adverse events
in liver reperfusion and thrombotic complications post cardiac surgery. It appears that
thrombopoietin is an acute phase reactant but not uniquely responsible for the rise in the
platelet count during a reactive thrombocytosis but is probably aided and abetted by IL-6 [70].
Platelets release CD40 ligand which induces tissue factor expression and increases inflamma‐
tory cytokines IL-6 and IL-8. (Esmon CT). The CD40 ligand is a transmembrane protein related
to TNF-α which was originally identified on stimulated CD4+ T cells. The interaction of CD40
on T and B cells is integral to the development and function of the humoral immune response.
It is now known that CD40 ligand is found on many cells including macrophages, endothelial
cells and platelets. Upon activation platelets express CD40L within seconds. As wtih TNF-α
and IL-1 the CD40L on platelets induces endothelial cells to exude cytokines and up regulate
the expression of adhesion molecules. This all increases the general recruitment of leukocytes
to the site of injury. Platelets therefore directly initiate the inflammatory response at the vessel
wall [14]. Figure 6
The concept that platelets play a key role in the host defence and inflammatory response has
taken longer to realise mainly due to their role in primary haemostasis. This new role of
platelets as immune effector cells is enhanced by the finding that platelets directly interact with
microbes and bacteria.
Platelet activation along with procoagulant events and fibrin formation seem crucial for the
containment and killing of bacteria. Platelets have recently been shown to induce the formation
of neutrophil extracellulat traps (NETs). NETs are lattice arrangements of decondensed nuclear
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chromatin which are laced with histones that have antimicrobial properties. It also appears
that this may be an ‘overshooting’ of the hosts defence mechanism with further platelet
activation, thrombosis and endothelial cell injury [71], [72], [73].
Figure 6. Inflammation and platelet activation. Platelet derived growth factor – PDGF, platetlet factor 4 – PF4.
6.4. Endothelium
Endothelial cells in the vasculature are actively involed in haemostasis providing an anticoa‐
gulant surface preventing activation of the coagulation system. Endothelial cells produce
elements with proinflammatory, procoagulant and antifibrinolytic properties as well as those
with the opposite anti-inflammatory, anticoagulant and profibrinolytic properties. When
endothelial cells are activated or damaged they release into the local surroundings procoagu‐
lant components such as von Willebrand factor ( a platelet binding factor and a carrier protein
for factor VIII) and thromboxane A2 (a platelet activator) and plasminogen activator inhibitor
(PAI-1 a potent inhibitor of tissue plasmingen activator). The opposite is true of components
that provide an anticoagulant surface in the milieu of the blood vascular barrier. Thrombo‐
modulin, a thrombin binding transmembrane protein that switches thrombin from a procoa‐
gulant enzyme to one that activates protein C, a nautral anticoagulant that inhibits the activity
of factors V and VIII, in internalised within the endothelial cell. Thrombomodulin is also
cleaved from the endothelium by activated Neutrophils. Tissue factor is expressed on the cell
surface along with adhesion molecules that mediate the interaction of neutrophils and platelets
these included vascular cell adhesion molecule (VCAM-1), P and E selectin and intracellular
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cell adhesion molecule (ICAM-1) all of which promote the inflammatory response. So the
endothelium serves as an interface for the inflammatory response leading to local activation
of the coagulation system, vasodilatation and pro-inflammatory state [3], [57].
6.5. Complement
Complement is part of the innate immune system and the effector of antibody mediated
immunity. The biological functions of complement include the defence against infections and
the clearance of immune complexes and apoptotic cells. The complement cascade is made up
of approximately 30 proteins circulating in plasma and expressed on cellular surfaces. The
complement cascade is activated via three pathways: classical, lectin and alternative. The
classical pathway is initiated by the binding of C1q to antigen–antibody complexes. The lectin
pathway is initiated via the binding of mannose-binding lectin or ficolins to sugars found at
the bacterial cell wall. Both of these pathways lead to the formation of a C3 convertase. The
alternative pathway is stimulated by spontaneous hydrolysis of internal thioester bonds within
C3. C3a and C5a are anaphylatoxins and inflammatory mediators which are inhibited by TAFI.
Complement and coagulation are again two systems that cannot be viewed separately during
an inflammatory response. Complement contributes significantly to the prothrombotic state
during inflammation. The direct procoagulant activities of complement involve the activation
of platelets via C3a and the C5b-9 membrane attack complex and the upregulation of tissue factor
and PAI-1 expression on various cell types by C5b. Thrombin has also recently been identified
as an activator of C5 linked to the coexistence of a C5 convertase enzyme [74], [75], [76].
It is of interest to note the complement factor C4B-binding protein is a positive acute phase protein
that can increase greater than 400% during inflammatory states. The C4B-bp in normal circum‐
stances binds the natural anticoagulant protein S. Protein S acts as a co-factor with activated
protein C in the inactivation of factors V and VIII. It was thought that an increase in C4B-bp may
increase the binding of circulating protein S, approximately 60% of protein S is normally bound
leaving the other 45% free protein S to aid in the V and VIII inactivation. However this in‐
crease is restricted to the C4BPα+ form, which does not bind to PS. Therefore, the blood levels
of the active free form of PS remain stable even during an acute phase response. The normal
binding of protein S to C4B-bp probably allows this complex to bind via protein S high affinity
for negatively charged phospholipids depositing it at area of cellular damage and limiting further
apoptosis through complement activation as it will block C4b (see Protein S).
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